Supreme Court to Weigh Liability of Generic Drug Makers for 'Skinny Label' Patent Infringement in Hikma v. Amarin
The upcoming Supreme Court decision in Hikma Pharmaceuticals USA v. Amarin Pharma could reshape pharmaceutical patent enforcement and marketing strategies by addressing whether ge…
On January 16, 2026, the U.S. Supreme Court granted certiorari to review a Federal Circuit ruling in Hikma Pharmaceuticals USA v. Amarin Pharma. The case centers on whether generic drug makers who exclude patented uses from their product labels—so-called 'skinny labels'—can still face patent infringement claims based…
